News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
MacroGenics reported a Q2 2026 profit driven by an $86.1 million gain from the sale of its CDMO operations for approximately $119.6 million. The company's total revenue significantly increased to $32.8 million due to a $24.5 million milestone from Sanofi and higher ZYNYZ royalty …
Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 5,006,752 shares of MacroGenics, Inc. common stock, which represents 7.88% of the outstanding class. Both Armistice Capital, as investment manager, and Steven Boyd, as its managing member, hold shared voting and dispositive …
Irenic Acquisition Corp. (IACQ) reported a net income of $1.37 million for the quarter ended June 30, 2026, primarily from $1.53 million in interest on its $254 million trust account. The SPAC has $254.06 million in its Trust Account and $1.02 million in cash …
MacroGenics Inc (NASDAQ: MGNX) reported second-quarter earnings per share (EPS) of $-1.10, missing analyst estimates by $1.02, and revenue of $32.83M, which fell short of the consensus estimate of $59.14M. The company's stock has seen significant volatility, being down 4.00% in the last three …
MacroGenics (NASDAQ: MGNX) reported a Q2 2026 adjusted EPS of $(0.27), significantly missing the $(0.13) estimate, and revenue of $32.832 million, falling short of the $67.456 million forecast despite a 47.62% YoY increase. The company posted a net income of $19.5 million, a turnaround …
MacroGenics reported its second quarter 2026 financial results, highlighting a significant corporate restructuring including the sale of its manufacturing operations for $122.5 million. This transition to a fully outsourced model has streamlined the company, reducing its workforce to approximately 140 people to focus on …
* MacroGenics press release [https://seekingalpha.com/pr/20619132-macrogenics-reports-second-quarter-2026-financial-results-streamlined-operating-model-and] (MGNX [https://seekingalpha.com/symbol/MGNX]): Q2 GAAP EPS of -$1.10 misses by $1.02. * Revenue of $32.83M (+377.9% Y/Y) misses by $26.31M. MORE ON MACROGENICS * MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important [https://seekingalpha.com/article/4925873-macrogenics-whipsaws-on-clinical-data-but-the-big-picture-is-still-important] * MacroGenics: 'Hold' …
MacroGenics Inc. (MGNX) reported second-quarter earnings of $19.5 million, or 31 cents per share, significantly exceeding Wall Street's expectation of a 40-cent loss per share. However, the biopharmaceutical company's revenue of $32.8 million fell short of the $44 million forecast by analysts. The earnings …
Wasatch Advisors LP significantly increased its stake in MacroGenics (NASDAQ:MGNX) during the second quarter, purchasing an additional 459,180 shares to bring its total ownership to over 2 million shares, valued at approximately $9.3 million. This increase means Wasatch Advisors now owns 3.18% of the …
MacroGenics, Inc. announced that Gilead Sciences, Inc. has exercised its option to obtain an exclusive license for a preclinical bispecific program, triggering a $10 million payment to MacroGenics. This program incorporates MacroGenics’ TRIDENT® platform and targets solid tumors. MacroGenics remains eligible for up to …
MacroGenics Inc. shares rose 4.3% after Gilead Sciences exercised its option on a preclinical bispecific program, resulting in a $10 million payment to MacroGenics. This exercise is part of a 2022 collaboration agreement, under which MacroGenics could receive up to $1.6 billion in additional …
MacroGenics Inc is projected to report a loss of 13 cents per share. This information is part of an earnings preview, indicating an upcoming financial announcement from the company. The full article is available through a subscription to TradingView.
This article provides an earnings forecast for Enel Chile SA (ENIC), indicating a current earnings forecast score of 7.33 and ranking 26th in the Electric Utilities & IPPs industry. Based on analysis from 3 analysts, the average price target is $3.90, with a consensus …
This article from Barchart.com provides a comprehensive guide to the price history and related financial data for Irenic Acquisition Corp. Cl A (IACQ) stock. It details how users can access and download historical data, including daily prices, latest trades, and corporate actions, and explains …
This article first appeared on GuruFocus. Release Date: August 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Galenica Ltd (WBO:GALE) achieved strong sales growth of 7.1% to CHF2.136 billion and increased adjusted …
MacroGenics (NASDAQ:MGNX) is anticipated to release its Q2 2026 earnings before market open on Thursday, August 13th. Analysts project a loss of approximately $0.08 per share and revenue of about $59.1 million. The company's prior quarter missed EPS expectations but exceeded revenue estimates, and …
An analysis by Intellectia AI suggests that Irenic Acquisition Corp (IACQ) is not a good buy for beginner long-term investors due to its flat stock price, lack of clear trends, and absence of significant catalysts or proprietary buy signals. The recommendation is to hold …
This article provides financial data specifically on the diluted earnings per share (diluted EPS) for Irenic Acquisition Corp. (BOATS:IACQW). It highlights the company's financial overview within the context of the stock market, noting that the market was closed with no trades. The content is …
dsm-firmenich Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), August 4, 2026 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 9, 2026 its intention to repurchase ordinary shares with an aggregate …
A holder of MacroGenics Inc. (NASDAQ: MGNX) has filed a notice under Rule 144 to sell up to 20,166 shares of common stock through Merrill Lynch. The proposed sale date is August 3, 2026, on NASDAQ. These shares were acquired through stock plan activity …
Bank of America Corporation has filed an amended Schedule 13G, disclosing a beneficial ownership of 2,556,475 shares of MacroGenics, Inc. common stock, which constitutes 4.0% of the class. This stake is held through various wholly-owned subsidiaries and Bank of America reports shared voting and …
MacroGenics, Inc. (NASDAQ:MGNX) has received a consensus "Hold" rating from seven brokerages, with an average 12-month price target of $5.50. This comes after some analysts raised their price targets and upgraded ratings, while others maintained a sell rating. The biopharmaceutical company recently reported a …
Renaissance Technologies LLC has reduced its stake in Enel Chile S.A. (NYSE:ENIC) by selling 374,400 shares, now holding 2.69 million shares valued at approximately $10.6 million. Despite this sale, other institutional investors have increased their positions in the company. Enel Chile reported quarterly revenue …
Search by ticker symbol or company name and select a result to open its chart.